Congress Asset Management Co. MA grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 3.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 37,012 shares of the medical research company’s stock after buying an additional 1,110 shares during the period. Congress Asset Management Co. MA’s holdings in Amgen were worth $6,375,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently modified their holdings of the business. Jackson Grant Investment Advisers Inc. raised its position in shares of Amgen by 0.6% during the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after purchasing an additional 4 shares during the period. Investment Partners Ltd. OH ADV raised its position in shares of Amgen by 0.5% during the second quarter. Investment Partners Ltd. OH ADV now owns 2,192 shares of the medical research company’s stock worth $377,000 after purchasing an additional 11 shares during the period. Conservest Capital Advisors Inc. raised its position in shares of Amgen by 0.4% during the second quarter. Conservest Capital Advisors Inc. now owns 3,130 shares of the medical research company’s stock worth $539,000 after purchasing an additional 13 shares during the period. Arvest Bank Trust Division raised its position in shares of Amgen by 0.9% during the second quarter. Arvest Bank Trust Division now owns 1,508 shares of the medical research company’s stock worth $260,000 after purchasing an additional 13 shares during the period. Finally, M Holdings Securities Inc. raised its position in shares of Amgen by 0.6% during the first quarter. M Holdings Securities Inc. now owns 2,825 shares of the medical research company’s stock worth $463,000 after purchasing an additional 18 shares during the period. Hedge funds and other institutional investors own 78.14% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was originally published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://transcriptdaily.com/2017/09/17/amgen-inc-amgn-holdings-boosted-by-congress-asset-management-co-ma.html.
AMGN has been the topic of a number of research analyst reports. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $189.00 price target on shares of Amgen in a research report on Friday, June 30th. BidaskClub raised Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. Jefferies Group LLC reaffirmed a “hold” rating and set a $180.00 price target on shares of Amgen in a research report on Monday, May 22nd. Credit Suisse Group set a $177.00 price target on Amgen and gave the stock a “hold” rating in a research report on Friday, July 14th. Finally, Morgan Stanley raised their price target on Amgen from $183.00 to $184.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 13th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. Amgen presently has an average rating of “Buy” and an average price target of $186.14.
Amgen Inc. (AMGN) opened at 187.47 on Friday. The firm’s 50 day moving average price is $175.31 and its 200 day moving average price is $169.32. The firm has a market cap of $136.79 billion, a price-to-earnings ratio of 17.08 and a beta of 1.35. Amgen Inc. has a 52-week low of $133.64 and a 52-week high of $191.10.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping the consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the business posted $2.84 earnings per share. Equities research analysts anticipate that Amgen Inc. will post $12.57 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Thursday, August 17th were paid a $1.15 dividend. This represents a $4.60 annualized dividend and a dividend yield of 2.45%. The ex-dividend date of this dividend was Tuesday, August 15th. Amgen’s dividend payout ratio (DPR) is presently 41.93%.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.